Showing 20 of 21 recruiting trials for “non-dystrophic-myopathy”
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
RecruitingNCT06747884 ↗
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
👨⚕️ Nicholas Johnson, MD, MSCI, FAAN, Virginia Commonwealth University📍 1 site📅 Started Jun 2025View details ↗
RecruitingNCT07385443 ↗
The Spanish National Registry for Myotonic Dystrophy Type 1
👨⚕️ Gisela Nogales Gadea, Ph.D., Germans Trias i Pujol Research Institute📍 8 sites📅 Started Jun 2025View details ↗
RecruitingNCT07362875 ↗
Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy
👨⚕️ Araya Puwanant, MD, Wake Forest University Health Sciences📍 1 site📅 Started May 2025View details ↗
Music Intervention for Brain-Heart Disease in Myotonic Dystrophy Type 1 (DM1)
A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
👨⚕️ Pascal LAFORÊT, MD, PhD, Neurology Department, Raymond Poincaré Hospital, APHP📍 1 site📅 Started Nov 2024View details ↗
Study of ATX-01 in Participants With DM1
Vasodilator and Exercise Study for DMD (VASO-REx)
👨⚕️ Tanja Taivassalo, Ph.D., University of Florida, College of Medicine, Department of Physiology and Aging📍 1 site📅 Started Jun 2024View details ↗
Pelvic Floor Muscle Training for Women with Myotonic Dystrophy
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
👨⚕️ Joanne M. Donovan, MD, PhD, Edgewise Therapeutics, Inc.📍 46 sites📅 Started Nov 2023View details ↗
RecruitingNCT06378216 ↗
Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
RecruitingNCT05224778 ↗
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
👨⚕️ Nicholas E. Johnson, MD, Virginia Commonwealth University📍 5 sites📅 Started Aug 2022View details ↗
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
👨⚕️ Harriet Gray-Stephens, BM BCh, MA (Oxon), MFPM, AMO Pharma📍 14 sites📅 Started Aug 2021View details ↗
Enrolling by InvitationNCT06101940 ↗
A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China
RecruitingNCT05020002 ↗
Extracellular RNA Biomarkers of Myotonic Dystrophy
👨⚕️ Thurman M. Wheeler, MD, Massachusetts General Hospital📍 3 sites📅 Started Dec 2020View details ↗
RecruitingNCT03981575 ↗
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
👨⚕️ Nicholas Johnson, MD, Virginia Commonwealth University📍 17 sites📅 Started Jan 2019View details ↗
RecruitingNCT05019625 ↗
Biomarker Development for Muscular Dystrophies
👨⚕️ Thurman M. Wheeler, MD, Massachusetts General Hospital📍 5 sites📅 Started Feb 2015View details ↗
RecruitingNCT02069756 ↗
The Duchenne Registry
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →